2. Design in Pharmaceutical Product Development 1.
-
Upload
sammy-hull -
Category
Documents
-
view
230 -
download
5
Transcript of 2. Design in Pharmaceutical Product Development 1.
![Page 1: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/1.jpg)
2. Design in Pharmaceutical Product Development
1
![Page 2: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/2.jpg)
Design & Selection of Drug Substance
2
![Page 3: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/3.jpg)
High Failure Rate
• For every 10,000 NCE’s in Discovery 10 enter pre-clinical development 5 enter human trials 1 is approved
• Interestingly….. Winning the lottery 1 in 5,200,000 A Royal Flush in Poker 1 in 650,000 Struck by lightning 1 in 600,000 Appear on the Tonight Show 1 in 490,000 Discovery to Market 1 in 10,000 A son who will play pro football 1 in 8000
3
Make, screen & push more compounds into the pipeline!
![Page 4: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/4.jpg)
‘HITS’
DevelopabilityScreens
In Silico Screening
Optimisation
DRUGPRODUCT
Lead Compounds
Combinatorial Chemistry
High ThroughputScreening
4
![Page 5: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/5.jpg)
Combinatorial Chemistry & HTS: Poor Solubility
Drug Discovery Before 1990
• lead compounds - drug like
• potency improved by adding lipophilic moieties
• low mol. weights circa.300
Drug Discovery After 1990• advent of HTS
• uses organic solvents to screen in vitro potency
• lead optimisation occurs by – increasing mol. weight – lipophilicity
540 % of compounds made each year are abandoned due to poor
solubility- Giovani Sala, Elan Pharma
Brick Dust !
![Page 6: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/6.jpg)
hundreds of compounds evaluated in parallel using rapid, high throughput predictive assays
CombinatorialLibrary
Potency Selectivity Kinetics Tissue penetration Carcinogenicity Physicochemical
Properties
Drug candidate
Increase choice Improve selection
Preformulation and Developability Screening
6
![Page 7: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/7.jpg)
Solubility: Double Edged Sword
• Relative difficulty in formulation design*
– poor permeability
– high first pass metabolism
– poor chemical stability
– low solubility
– instability in GI fluids
– high dosage
• More flexibility in altering physical chemistry then physiology
– absorption rate can vary from 0.001 - 0.05 min-1 i.e. x 50
– solubility can vary from 0.1 µg - 100 mg/ml i.e. x 1000,000
– target solubility is 1mg/ml (covers 1 mg to 500 mg oral dose)
7• Taken from a survey of formulation scientists
from 12 companies in Japan
least
most
![Page 8: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/8.jpg)
GIT Physiology
• Potential for chemical degradation under different pH’s
• Changes in mucosal SA, presence of specific absorption windows
• Influence of endogenous secretion along the GI-tract
• Influence of gastric emptying, transit time and food dependency
• Influence of hydration state and water availability along GI-tract
• Pre-systemic availability – membrane/faecal binding & metabolism
8
![Page 9: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/9.jpg)
Gastro Intestinal Tract conditions
• Absorbing surface area of the colon (~0.3m2) very small c.f. rest of GIT (120-200m2)• High viscosity of lumen contents can compromise drug diffusion and therefore absorption• Long residence times (up to 16 hrs)• Densely populated with microbial flora 9
![Page 10: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/10.jpg)
Predicting good oral absorption
Increasing dose
Incr
easi
ng
per
mea
bil
ity
250 500 1000 10000 100000
Volume (ml) required to dissolve the dose5000
10
1
0.1
Pre
dic
ted
Pe
rme
ab
ility
in H
um
an
s (c
m/s
ec
x10-4
)
Class I
Good solubility andpermeability
Class IIIGood solubility,
poor permeability
Class IVPoor solubility and
permeability
Class IIa (dissolution rate limited)
Class IIb (solubility
limited)
Jejunal solubility (e.g. FaSSIF)
Poor solubility, good permeability
Good Difficult
Poor Very poor
Particle size reduction or other bio-enhancement required
Increasing solubility
Dose/solubility ratio
Butler & Dressman, JPharmSci. Vol 99, Issue 12, pp 4940–4954, Dec 2010
![Page 11: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/11.jpg)
Physico-chemical methods for Boosting Oral Absorption*
• Use a Form with higher solubility
• more soluble polymorph
• more soluble salt
• amorphous c.f. crystalline form
• Formulate so drug is in solution
• Increase rate of dissolution
• particle size
11*many principles applicable for parenteral delivery
![Page 12: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/12.jpg)
Use a form with higher solubility
12
![Page 13: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/13.jpg)
Crystal Form
• Depending on crystallising conditions, actives may exhibit:
– different habits
– different polymorphs
– solvates (solubility: organic > non solvate > aqueous solvate)
• Polymorphs with lowest free energy (lowest solubility) tend to be more thermodynamically stable
– metastable (more soluble) form less soluble form
– smaller the difference in free energy the smaller the difference in solubility
– could we use metastable form for safety assessment?
13
![Page 14: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/14.jpg)
0
5
10
15
20
25
0 6 12 18 24
100% B
50%A &50%B
100% A
Serum Levels: Chloramphenicol Palmitate
Effect of Polymorph Type
14
![Page 15: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/15.jpg)
Crystal Form
Polymorphicform
Cmax
(g/ml)tmax
(hr)AUC
(g.h/ml)
I 44 3 226
II 85 2 590
III 80 3 576
15
Bioavailability of tolbutamide polymorphs in dogs
![Page 16: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/16.jpg)
Amorphous forms• Amorphous forms afford better solubility & faster dissolution rates
c.f. crystalline forms– e.g. novobiocin, troglitazone
• Amorphous forms can transform to a more stable, but less soluble crystalline state
– tendency to transform is related to Tg & storage temp
– Tg > 80oC for amorphous solids to remain stable at RT
– for investigative studies low temperature storage to retain amorphous form is viable
– can stabilise by formulating with excipients of higher Tg
• PVP (Tg, 280oC) inhibits crystallisation of Indomethacin
• melt-extrusion with PVP to form granules or tablets 16
![Page 17: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/17.jpg)
Granulator
Shaping Device
Tablets
PolymerExcipientDrug
Granulation
Pellets
Schematic view of Melt Extrusion
17
![Page 18: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/18.jpg)
Plasma Profile data for SB-Compound
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0.0 4.0 8.0 12.0 16.0 20.0 24.0
Time (Hours)
Pla
sm
a C
on
cen
trati
on
(u
g/m
L)
Melt Extrusion
SuspensionMicronised Drug
18
![Page 19: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/19.jpg)
pH adjustment & Salt Form
• Any drug moiety with a pKa between 3-11 can potentially be solubilised by pH modification
• Salt-Formation is an extension of pH adjustment. Most common forms are as follows:
– acidic drugs: sodium>potassium>calcium
– basic drugs: hydrochloride>sulphate>mesylate
>chloride>maleate>tartrate>citrate
• Salt-form requires agreement from all development parties– highly soluble form might be hygroscopic & unstable
choose the best ‘all-rounder’ 19
![Page 20: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/20.jpg)
pH Solubility Profiles
• Intrinsic solubility (S0) region – pH range in which compound is completely unionized and has the lowest solubility.
• Ionized region – region around pKa of compound. At pKa are equal amounts of ionized and unionized forms of the compound in solution. For every pH unit change either side of the pKa gives a 10-fold change in amount of ionized drug in solution. Implications for lab measurements (pH control), & GI pH/ absorption. Compound precipitating in this region can be as free base or salt (depends upon the strength of solid-state interactions).
• pHmax – the region where compound has maximum solubility (equilibrium solid state form will be a salt i.e. completely ionized drug associated with oppositely charged counter-ions).
• Salt plateau – pH range in which the molecule is fully ionized and the salt solubility of the compound predominates. Solubility value is dependent upon strength of solid-state interactions with the counter-ion forming the salt. (Common ion effects & solvent can impact solubility.)
20
Weak Base
Solubility=S0(1+10(pKa-pH) )
S0=intrinsic, solubility of free acid/base
SO=0.528mg/mlpKa5.54
![Page 21: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/21.jpg)
Classical pH-Solubility profile
S0=intrinsic, solubility of free acid/base
![Page 22: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/22.jpg)
Salt Form
compound solubility in water (mg/ml)
RPR-127963 free base not detected
hydrochloride 3.9
mesylate 108
citrate 0.8
tartrate 0.9
sulphate 50
22
Aqueous solubilities of RPR-127963 salts
• Sulphate was progressed into development
• Could use a more soluble form for investigative studies?
![Page 23: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/23.jpg)
Plasma Profiles for U-103017 in the Beagle Dog @ 10 mg/kg
0
20
40
60
80
100
120
140
160
0.0 2.0 4.0 6.0 8.0
Time (Hours)
Pla
sm
a C
on
cen
trati
on
(u
M)
Di-SodiumSalt
Free AcidSuspension
23
![Page 24: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/24.jpg)
Formulate so drug is in solution
24
![Page 25: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/25.jpg)
Solubilising Vehicles: organic solvents
Solvent Compounds
cremophor(polyoxymethylated castor oil)
miconazole, paciltaxel
dimethylacetamide tensoposide, busulfan
ethanol diazepam, phenytoin
glycerin epinephrine,idarubicin
PEG 300 and 400 lorazepam, etoposide
propylene glycol phenobarbital, hydralazine
sorbitol nicardine, triamcinolone
polysorbate 80 dexamethasone, docetaxel
25
Organic solvents used in commercial parenteral formulations
![Page 26: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/26.jpg)
Solubilising Vehicles
Solvent/Cosolvent Issue
Polyethylene glycol Laxative, LMW residues
Propylene Glycol Dose limitation
Ethanol Effect of chronic dosing
Dimethyl Acetamide Irritation
Oily Vehicles Solubilising limitations
26
![Page 27: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/27.jpg)
Complexation:CyclodextrinsEnhance the Drug’s Water Solubility
Increase Drug’s Aqueous Solution Stability
Improve Solubility & Dissolution: Improve Oral Bioavailability
Effective Delivery
Drug:CDComplex
Lipophilic Cavity
Hydrophilic Exterior
OH
CH2OH
HO
CHCH
1:1 Complex
Lipophilic
Drug
27
![Page 28: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/28.jpg)
Plasma Profiles of Glibenclamide (3 mg dose) in dogs
0
100
200
300
400
500
600
700
0 4 8 12 16 20 24
Time (Hours)
Pla
sm
a C
on
cen
trati
on
(n
g/m
L)
Captisol Complex
Crystalline Material
28
![Page 29: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/29.jpg)
Complexation:Cyclodextrins
Species
i/v AUC
(mgh/ml)
cyclodextrin AUC
(mgh/ml)
m/cellulose suspension
AUC (mgh/ml)
mouse 137.0 143.0 63.7
rat 89.4 58.6 43.0
dog 89.4 58.6 43.0
monkey 115.0 59.4 15.9
29
Bioavailability of Sch-56952 (azole anti-fungal) in animals
![Page 30: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/30.jpg)
Increase rate of dissolution
30
![Page 31: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/31.jpg)
Solubility & Dissolution Rate
Dissolution Rate
D.Ae.Cs R
Where
D = Diffusion Coefficient
Ae = Effective Surface Area
Cs = Saturation Solubility
R = Thickness of Diffusion Layer
Surface Area as a function of Particle Size
-1.0E+5
0.0E+0
1.0E+5
2.0E+5
3.0E+5
4.0E+5
5.0E+5
6.0E+5
7.0E+5
8.0E+5
0.01 0.1 1 10 100
Particle diameter (um)
Spe
cifi
c S
urfa
ce A
rea
(cm2 /c
m3 )
31
![Page 32: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/32.jpg)
Danazol Bioavailability (Dog)
32
0
0.5
1
1.5
2
2.5
3
3.5
0 5 10 15 20 25 30
Time (hrs)
Dan
azo
l (u
g/m
l p
lasm
a)
Conventional Suspension (n=5)
Nanoparticulate Dispersion (n=5)
Cyclodextrin Complex (n=5)
![Page 33: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/33.jpg)
The NanoCrystal™ Advantage
• Rapamune (Wyeth)– Sirolimus – Immunosuppressant– was available as a sachet &
reconstituted suspension– required storage in a fridge
• Using Nanocrystals– possible to supply a solid oral
tablet formulation– more stable– more convenient
33
![Page 34: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/34.jpg)
Comparison of U-103017 Formulations @ 10 mg/kg in the Beagle Dog
050
100150200250300350400450500
Sol
utio
ns
Di-N
a S
alt
Am
orph
ous
Sus
p
Bul
k D
rug
caps
ule
Sus
pens
ion
Mill
ed S
uspe
nsio
n
Sub
-Mic
ron
Sus
pens
ion
HP
MC
-P D
ispe
rsio
n
PV
P D
ispe
rsio
n
PE
G 3
350
Sol
id
Gel
ucire
Sol
id
Sal
t Spr
ay D
ried
40%
Sal
t Bea
d C
ap
AU
C (
uM
.hr)
Reference 14Reference 1434
![Page 35: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/35.jpg)
35
Regardless of route a drug needs to dissolve first!
Take Home Message
![Page 36: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/36.jpg)
Formulating the drug substance into a Product
36
![Page 37: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/37.jpg)
Requirements of a Dosage Form
• Contains an Accurate Dose.
• Makes drug available for absorption (oral dosage).
• Is stable (retains quality).
• Convenient to take or administer.
• Is produced economically by an acceptable process.
37
![Page 38: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/38.jpg)
Effect on Drug
“Know your Dosage Form”
Optimise Levelsof Excipients
Addition of other materialsEngineering Technologies
Physical Modifications
Compensate forDeficiencies
“Know your Drug”
Formulation Development
38
![Page 39: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/39.jpg)
Functions of Excipients
• Compensate for deficiencies in the drug
• Aid manufacture of the dosage form
• Quality assurance and maintenance
• Identity, patient acceptability– colour– taste
• “Target” the drug to site of activity– absorption– site-specific delivery
39
![Page 40: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/40.jpg)
Standards for Excipients
• Must not interact (adversely) with the drug
• Must not compromise safety or tolerance
• Function in the manner intended
40
![Page 41: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/41.jpg)
Factors affecting performance of oral dosage forms
• particle size of active
• granulation– granulating agents
– mode of granulation
• lubricant– type
– degree of mixing
• compression force
• film coat
41
All need to be evaluated: CMC section of regulatory submission
![Page 42: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/42.jpg)
Clinical Studies
42
Phase I absorption, metabolism, tolerance (volunteers)
Phase 2A “does the drug work” ? (efficacy)
“ 2B dose/dose regimen
Phase III “how good is it”
Phase IV post-marketing studies
Ideal that the same formulation is used at all stages
![Page 43: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/43.jpg)
Dosage Forms for Clinical Programmes
43
Phase One Flexibility of Dose- powder in bottle- capsule- tablet
Phase Two Range of Doses in “look-alike” units- tablet- capsule
Phase Three Formulation for Marketing
FDA will not consider tablets & capsules as bioequivalent!
Tablets more popular than capsules (smaller & more stable)
![Page 44: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/44.jpg)
What does a dose look like?
44
Preclinical stage Phase 1 stagePhase 2 stage
Phase 2/3Phase 4 stages
![Page 45: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/45.jpg)
Why do Formulations Change ?
• Technical problems
• Need to incorporate different doses
• Nature of clinical programmes
45
![Page 46: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/46.jpg)
Formulation and the Stock Market
46
“To Merck’s dismay, Monsanto completed its clinical studies first. Among the reasons was a dosage glitch at Merck. The company found that, instead of 1000mg, the proper dose was 12.5-25mg. The pills that resulted were so tiny that Merck was afraid that Arthritis patients wouldn’t be able to pick them up.
It enlarged them with edible filler but that caused another problem. The fiber turned out to slow the drug’s absorption. Three months were lost while researchers worked to fix this”
Wall Street Journal January 10th 2001
![Page 47: 2. Design in Pharmaceutical Product Development 1.](https://reader034.fdocuments.us/reader034/viewer/2022050920/551b3413550346d41a8b501b/html5/thumbnails/47.jpg)
Impact of changing dose!
Very difficult to accommodate large changes in dose, as it
will influence processing & manufacturing on scale-up
47